Taysha Gene Therapies

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Taysha Gene Therapies advances TSHA-102 trials, secures financial stability

Taysha Gene Therapies showcased positive TSHA-102 trial results, faced financial challenges with increased expenses, and highlighted the potential of gene therapy in treating Rett syndrome. The company's focus on safety, sustained improvements, and regulatory advancements positions it for future success.

Taysha Gene Therapies reports positive TSHA-102 data and financial growth

Taysha Gene Therapies showcased promising advancements in the TSHA-102 program for Rett syndrome, supported by positive clinical data and a strengthened financial position.
While challenges exist in regulatory clarity and cost management, the company's strategic focus on data integrity and patient safety bodes well for future growth.
Opportunities for expansion, regulatory milestones, and market positioning through effective resource allocation and research advancements position Taysha for continued success.

Taysha Gene Therapies advances TSHA-102 program with FDA approvals

Taysha Gene Therapies showcased positive progress in their TSHA-102 program for Rett syndrome, securing FDA approvals and demonstrating promising safety profiles in high-dose patients.
While challenges exist in regulatory discussions and optimizing dosing strategies, the company's proactive approach, strategic alliances, and ongoing enrollment position them well for future success.
Excitement for 2025 lies in the company's active enrollment sites, dosing progress, and the potential for improved outcomes in pediatric patients, signaling a positive trajectory for Taysha Gene Therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month. Company was forced to cut 35% of workforce, stop construction of its cGMP manufacturing facility and focus on two lead clinical candidates.

Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder and Chief Executive Officer Suyash Prasad - Chief Medical Officer and Head of Research and Development Kamran Alam - Chief Financial Officer Fred Porter - Chief Technical Officer Conference Call Participants Gil Blum - Needham & Company, LLC Geulah Livshits - Chardan Mehdi Goudarzi - Truist Securities Michael Ulz - Morgan Stanley David Hoang - SMBC Nikko Benjamin Paluch - Robert W. Baird Yanan Zhu - Wells Fargo Tiffany Marchell - William Blair Whitney Ijem - Canaccord Genuity Operator Thank you for standing by.

Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript

Abeona Therapeutics

McEwen Mining

National CineMedia

Oncolytics Biotech, Inc.

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Analysts, Targets Up To 995%

$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome

Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

In their previous filing dated October 5, 2020 they reported 5,295,307 shares and 14.30% of the company, an increase in shares of 32.00% and a decrease in total ownership of 3.10% (calculated as current – previous percent ownership).

Paul Manning increases stake in Taysha Gene Therapies Inc (TSHA)

DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended September 30, 2022, and host a corporate update conference call and webcast on Tuesday, November 8, 2022, at 8:00 AM Eastern Time.

Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8

DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the pricing of an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $2.00 per share. In addition, Taysha has granted the underwriter a 30-day option to purchase up to 2,100,000 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Taysha are expected to be approximately $28.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriter's option to purchase additional shares. The offering is expected to close on or about October 31, 2022, subject to customary closing conditions.

Taysha Announces Pricing of Public Offering of Common Stock

Faraday Future Intelligent Electric

Ideanomics Inc

Revelation Biosciences

Use these technical indicators for trading penny stocks right now The post Buying Penny Stocks? 3 Technical Indicators to Use  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks? 3 Technical Indicators to Use

DALLAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it intends to offer and sell, subject to market conditions, $30 million of shares of its common stock in an underwritten public offering. All shares of common stock to be sold in the offering will be offered by Taysha. Taysha also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock

Taysha Gene Therapies (NASDAQ: TSHA ) jumped 50% overnight after Japan's Astellas Pharma (OTCMKTS: ALPMY ) bought 15% of the company and exclusive marketing rights to its genetic therapies. Taysha is working on two Adeno Associated Virus (AAV) therapies for genetic brain disorders.

What Is Going on With Taysha Gene (TSHA) Stock Today?

Conference call and webcast on Tuesday, October 25 at 8:00 AM ET Conference call and webcast on Tuesday, October 25 at 8:00 AM ET

Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma's Strategic Investment to Support the Development of Taysha's AAV-based Gene Therapy Programs

- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic central nervous system diseases with serious unmet medical needs - - Astellas to invest a total of $50 million to acquire 15% of the company and to receive an exclusive option to obtain an exclusive license for TSHA-102 for Rett syndrome  and TSHA-120 for giant axonal neuropathy (GAN) - - Astellas to receive certain rights related to any potential change of control of Taysha - - Astellas to receive one Board observer seat on the Taysha Board of Directors - TOKYO and DALLAS , Oct. 24, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Taysha Gene Therapies, Inc. (NASDAQ: TSHA, CEO: RA Session II, "Taysha") today announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN.

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs

DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced two poster presentations at the upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT) in cooperation with the British Society of Gene & Cell Therapy (BSGCT) taking place in Edinburgh, Scotland from October 11-14, 2022.     Poster Presentation Details

Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder, and Chief Executive Officer Dr. Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Dr. Frederick Porter - Chief Technical Officer Conference Call Participants Joon Lee - Jo Securities Gil Blum - Needham & Company Mike Ulz - Morgan Stanley Eun Yang - Jefferies Jack Allen - Baird Yun Zhong - BTIG Sami Corwin - William Blair Rick Miller - Cantor Fitzgerald Operator Greetings. Welcome to the Taysha Gene Therapies Second Quarter 2022 Financial Results and Corporate Update Conference Call.

Taysha Gene Therapies, Inc. (TSHA) CEO RA Session on Q2 2022 Results - Earnings Call Transcript

TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natural history

Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the second quarter ended June 30, 2022, and host a corporate update conference call and webcast on Thursday, August 11, 2022, at 8:00 AM Eastern Time.

Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11

BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET

Taysha Gene Therapies to Participate in Upcoming August Investor Conferences

President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET

Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022

The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET

Taysha Gene Therapies Announces Annual Stockholder Meeting

Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET

Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session II - President, Founder, and Chief Executive Officer Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Conference Call Participants Gil Blum - Needham & Company Elizabeth Webster - Goldman Sachs Kevin DeGeeter - Oppenheimer & Company Jack Allen - Baird Yun Zhong - BTIG Laura Chico - Wedbush Securities Yanan Zhu - Wells Fargo Operator Good morning. Welcome to Taysha Gene Therapies' First Quarter 2022 Financial Results and Corporate Update Conference Call.

Taysha Gene Therapies, Inc. (TSHA) CEO RA Session II on Q1 2022 Results - Earnings Call Transcript

Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the first quarter ended March 31, 2022, and host a corporate update conference call and webcast on Monday, May 16, 2022, at 8:00 AM Eastern Time.

Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16

DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced oral and poster presentations and a company-sponsored symposium at the upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place in Washington, D.C. from May 16-19, 2022.

Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy

Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to estimated natural history decline of 24 points

News for Taysha Gene Therapies Stock (TSHA)